The aim of this study was to pharmacologically inhibit NOX4, by using the novel and specific NOX4 inhibitor GLX7013114 (Glucox Biotech AB, Sweden), to investigate the hypothesis that during the reperfusion phase this treatment strategy could preserve mitochondrial and renal function in a mouse model of IR-induced acute kidney injury (AKI). Here, NOX4 is linked to acute kidney injury.